Abstract
People involved with development of health care policy must be appreciative of the social and economic challenges that will likely develop as a result of the rise in Alzheimer’s disease (AD) as the 21st century progresses. Their attitudes, perceptions and understanding regarding AD were captured in the IMPACT survey, a 30-minute Web-based questionnaire. Fifty health policy managers and decision-makers (payors) were recruited, 10 each from 5 European countries—France, Germany, Italy, Spain and the United Kingdom. Most payors felt that AD was underdiagnosed and undertreated in their country (80% and 68%, respectively). Half of all payors felt that their government did not invest enough in treating AD, and 30% felt their government hindered access to drug therapy. Payors believed that treatment should be initiated as early as possible after a diagnosis of AD (82%), and that early treatment can delay progression of the disease (82%). Even more than caregivers, payors agreed that AD can have devastating effects on the family of the sufferer (90% vs 75%; P<0.05). Payors more often cited cancer, stroke and heart disease than AD as affecting their budgets, but cited AD more often than depression, diabetes, HIV/AIDs and arthritis. Cost savings were seen as the most important factor regarding policy decisions. These attitudes of the surveyed payors towards AD and the patients and caregivers affected by it suggest that they may advocate for national and international policies that will facilitate earlier diagnosis and improved access to treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Prevalence of dementia in Europe. Alzheimer Europe. Available at: http://www.alzheimer-europe.org/Our-Research/European-Collaboration-on-Dementia/Prevalence-of-dementia2/Prevalence-of-dementia-in-Europe. Accessed December 4, 2009.
Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112–2117.
Jones RW, Andrieu S, Knox S, Mackell J. Physicians and caregivers: ready and waiting for increased participation in clinical research. J Nutr Health Aging. 2010;14(7):563–568.
Bond J, Graham N, Padovani A, Mackell J, Knox S, Atkinson J. Screening for cognitive impairment, Alzheimer’s disease and other dementias: opinions of European caregivers, payors, physicians and the general public. J Nutr Health Aging. 2010;14(7):558–562.
Germain S, Adam S, Olivier C, et al. Does cognitive impairment influence burden in caregivers of patients with Alzheimer’s disease? J Alzheimers Dis. 2009;17(1):105–114.
Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F. Patients with Alzheimer’s disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neurol. 2003;16(3):140–145.
Leon J, Cheng CK, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Aff (Millwood). 1998;17(6):206–216.
Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer’s disease in France: the economic implications. Dement Geriatr Cogn Disord. 2004;17(1–2):5–13.
Grossberg GT. Impact of rivastigmine on caregiver burden associated with Alzheimer’s disease in both informal care and nursing home settings. Drugs Aging. 2008;25(7):573–584.
Lu S, Hill J, Fillit H. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer’s disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Am J Geriatr Pharmacother. 2005;3(2):92–102.
Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2002;72(3):310–314.
Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600–607.
Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24(2):138–145.
Wilkinson D, Schindler R, Schwam E, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;28(3):244–251.
Winblad B, Wimo A, Engedal K, et al. 3-Year study of donepezil therapy in Alzheimer disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006;21:353–363.
Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, for the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427–433.
Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004;63(2):214–219.
Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer’s disease. J Nutr Health Aging. 2006;10(5):417–429.
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2001;57(4):613–620.
Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–1341.
Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009;25:2577–2587.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Forette, F., Padovani, A., Berthet, K. et al. Implications of the impact survey for payors across Europe. J Nutr Health Aging 14, 553–557 (2010). https://doi.org/10.1007/s12603-010-0267-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-010-0267-7